Novartis wants to get people talking — about cardiovascular disease. Its new “From the Heart” video series talks to researchers, patients, public health officials and advocates. The interviewer is Marie-France Tschudin, Novartis’ president and chief commercial officer, who opens the series noting th…
openPRIs Novartis AG (NVS) a Winner in the Healthcare Sector?
Diabetes Drugs Market Global Outlook and Forecast 2021 2027 is latest research study released by HTF MI evaluating the market risk side analysis highlighting opportunities and leveraged with strategic and tactical decision making support The report provides information on market ...
Today’s Research Daily features new research reports on 12 major stocks, including Novartis AG (NVS), Lowe’s Companies, Inc. (LOW) and The Goldman Sachs Group, Inc. (GS).
Is Novartis AG (NVS) a Good Buy in the Drug Manufacturers - General Industry?
Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow.
The Idiopathic Membranous Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period.
“Delveinsight Business Research LLP”The Glomerulonephritis market size is expected to increase during the forecast period owing to the rise in the number
Novartis recently announced encouraging results from its clinical trial of its Prolia biosimilar.
Studycafe<p>Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.</p>
StudycafeJob Update: M.Com, CA, ICWA, MBA Vacancy at Novartis
StudycafeJob Update: M.Com, CA, ICWA, MBA Vacancy at Novartis
StudycafeA federal court has ruled a Beovu injection lawsuit can proceed after rejecting a motion to dismiss filed by Novartis on preemption grounds.
SURPERFORMANCEJob Update: M.Com, CA, ICWA, MBA Vacancy at Novartis
SURPERFORMANCEItem 1.01 Entry into a Material Definitive Agreement Second Amendment to License Agreement with Novartis On September 27, 2022, Allarity Therapeutics Europe Aps , a wholly-owned subsidiary of... | October 1, 2022
This press release was orginally distributed by SBWireNew Jersey, NJ -- (SBWIRE) -- 09/24/2022 -- The Probiotic Supplements Market has witnessed
Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the USAdvancing eight in-market brands with multi-billion dollar peak sales potential and prioritizing pipeline to focus on high-value NMEsContinu…
Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals court ruling, the Swiss drugmaker said on Wednesday.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/KXNNMD6KDBNJBEHT6C6ARJFJ7E.jpg)
<p>Having finally confirmed the Sandoz spin-off, Novartis will become a ‘pure play’ pharma company, and focused on picking bigger blockbuster winners from internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.</p>
STATAfter a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for ALS.
STAT
